Scrip
US FDA and industry face challenges on opioid class REMS
01 June 2009
Sue Sutter
A risk evaluation and mitigation strategy (REMS) for the long-acting opioid drug class should first be tested on a pilot basis, include technologies for tracking diversion and measure the programme's downstream effects, including whether new prescribing restrictions are leading to increased abuse of...
Please Login to read the full article.
01 June 2009
Sue Sutter
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
